To analyze the mechanism of olaparib resistance in pancreatic cancer cells with BRCA1 dysfunction, we first isolated four BRCA1 KO candidate clones obtained using the CRISPR/Cas9 system. This evidence concerns the gene BRCA1 and familial pancreatic carcinoma.